Official Presentation of the DeepChek® HPV Messenger RNA Genotyping Assay Webinar from June 26, 11h00 CET / Paris time https://ablsa-my.sharepoint.com/:f:/p/matthieu_barralon/EoLXon5w0g9AhQlr5kZTO_gBQ9TVE9AcQJuJu_Cw_9Y1Jw?e=OU2KLh
ABL Diagnostics Webinar Series Read More »
Julia Faillace Thiesen , Elise Jacquemet , Pascal Campagne, Denis Chatelain, Etienne Brochot, Yves‑Edouard Herpe , Nolwenn M. Dheilly , Fabrice Bouilloux, Bénédicte Rognon, Alexandre Douablin, Guillaume Leboucher , Florent Percher, Marc Eloit and Philippe Pérot Abstract Background Cervical cancer screening programs are increasingly relying on sensitive molecular approaches as primary tests to detect high‑risk
ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, is pleased to announce an exclusive distribution agreement with Riken Genesis Co., Ltd. (https://www.rikengenesis.jp/en.html). Under this partnership, Riken Genesis will promote and commercialize ABLD’s DeepChek® and UltraGene molecular assays across laboratories in Japan, further strengthening its diagnostics portfolio. Through this collaboration, Riken Genesis
REAL LIFE EXPERIENCE: The relevance of ultradeep sequencing for low HIV‐1 viral loads and proviruses in the clinical setting Webinar from Tuesday November 19, 2024 – 4pm CEST https://ablsa-my.sharepoint.com/:f:/p/matthieu_barralon/EoLXon5w0g9AhQlr5kZTO_gBQ9TVE9AcQJuJu_Cw_9Y1Jw?e=OU2KLh
ABL Diagnostics Webinar Series Read More »
NEWBURYPORT, MA, UNITED STATES, September 23, 2024 /EINPresswire.com/ — AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, is pleased to announce today the execution of a co-marketing agreement to co-promote in the USA Next Generation
The relevance of ultradeep sequencing for low HIV-1 viral loads and proviruses in the clinical setting Alizée Foury 1 2, Aline Saunier 2, Audrey Taverniers 2, Nathalie Pinet 2, Thomas Josse 2, Eliette Jeanmaire 3, Caroline Emilie 3, Evelyne Schvoerer 2 4, Cédric Hartard 2 4 Abstract Improving the therapeutic management of HIV-positive persons is a major public health issue and includes better detection of drug resistance mutations (DRMs). The aim of this study was
https://pubmed.ncbi.nlm.nih.gov/39185639/ Read More »
WOIPPY, FRANCE, August 21, 2024 /EINPresswire.com/ — ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories today announced its DeepChek® offer for SARS-CoV-2 Assays & Software, able to identify, to distinguish and to monitor circulating SARS-CoV-2 variants, indicative of COVID-19 infection and related epidemics, has
WOIPPY, FRANCE, July 16, 2024 /EINPresswire.com/ — ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the execution of an exclusive distribution agreement to confer to Interlux OÜ (https://www.linkedin.com/company/interlux-estonia/ ) the rights to promote and commercialize ABLD assays and software
Management of the APOBEC Mutations through the DeepChek-HIV Proviral DNA Genotyping Assays & Software OVERVIEW & USERS EXPERIENCE Webinar from Thursday June 13, 2024 – 4pm CEST
ABL Diagnostics Webinar Series Read More »
Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce the involvement of its entire team to support fight against Respiratory Syncytial Virus (RSV). Even if RSV is a common respiratory virus that usually causes mild, cold-like symptoms,
ABL Diagnostics Deeply Involved to Support Fight Against RSV Infection Read More »
